PARIS (Reuters) – French healthcare company Sanofi on Thursday said it was ending a programme evaluating tusamitamab ravtansine related to the treatment of types of lung cancer.
(Reporting by Sudip Kar-Gupta; Editing by Christopher Cushing)
Sanofi to end cancer research programme evaluating tusamitamab ravtansine
Dec 21, 2023 | 1:46 AM
